Aurin Biotech Inc. is a private company established to advance the development of a remarkable collection of small molecules that can block self-attack due to abnormal activation of the body’s own complement system. Such attack has been reported to occur in a wide spectrum of conditions where disease-modifying treatments are urgently need.
The company was founded to advance the discoveries made by the McGeer and Associates Laboratory at the University of British Columbia (UBC). Dr. Patrick L. McGeer is Canada’s most cited neuroscientist. Both he and his wife, Dr. Edith McGeer, are in the top 100 most cited neuroscientists in the world and their laboratory is well known for their work in neuroinflammation and neurodegenerative disorders, particularly Alzheimer disease. In seeking new pharmaceuticals for the treatment of such diseases, their team discovered a collection of remarkable molecules that are capable of inhibiting a complex biochemical pathway — called the complement system — that is involved in a spectrum of human diseases. Read more
Aurin Biotech was founded by two of the world’s most cited neuroscientists and their hand-picked team. Our tightly knit company is led by its founders and is supported by a talented Board and management team. Read more
- President and CEO — Dr. Patrick L. McGeer
- Vice President — Dr. Edith G. McGeer
- Chief Financial Officer — Nizar Bharmal
- Corporate Counsel — Stephen Tong
- Business Development — Christopher J. Campbell
Board of Directors
- Dr. Patrick L. McGeer, MD, PhD, FRCP(C), FRSC, FAAAS
- Dr. Edith G. McGeer, PhD, FRSC
- Dr. Douglas Bell, MD, FRCS(C)
- Dr. Andrew von Flotow, PhD
- Dr. Hagen Kennecke, MD, FRCP(C)
Our research and development strategy is driven by basic science. Our scientists focus on understanding the role that aberrant complement activation plays in disease pathophysiology, so that we can investigate the potential for our expanding drug development pipeline to provide relief. Although complement is an essential defense system, it is widely regarded as a double-edged sword. Its initial (opsonizing) phase is beneficial, but the terminal cascade, if not rigidly controlled, is self-damaging. Read more Read more
Self-attack by the body’s own complement system is known to occur in many human diseases. Some of the diseases where complement activation has been reported to exacerbate the underlying pathology include paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremia syndrome (aHUS), age related macular degeneration (AMD), Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), neuromyelitis optica (NMO), Parkinson disease (PD), rheumatoid arthritis (RA), atherosclerosis, pemphigus, psoriasis, allergic dermatitis and organ transplant rejection. Our research program is designed to provide disease-modifying treatments for these and related disorders. Read more
Our drug development program focuses on a collection of innovative therapeutic candidates that have the potential to become first-in-class and best-in-class therapies. Our lead drug candidate (AUR1107) is orally effective and readily crosses the blood brain barrier. It holds promise to become one of the most wide spectrum drugs ever developed. Read more
We strive to protect the integrity of our drug candidates through a variety of methods, including patent protection for our products and compositions, their methods of use and processes for their manufacture. Foundational intellectual property (IP) rights have been assigned to Aurin Biotech by the inventors. We seek international patent protection and routinely file patent applications for new commercially valuable inventions in order to protect our expanding IP portfolio. Our patent portfolio is currently composed of US and PCT patent applications.
Our business philosophy values collaboration and partnering. We are engaged in several research programs involving industry and academic partners. If your organization would be interested in collaborating we would be pleased to hear from you.